Lexicon Pharmaceuticals (NASDAQ:LXRX) released its quarterly earnings results on Thursday. The biopharmaceutical company reported $2.11 earnings per share for the quarter, topping analysts’ consensus estimates of $1.31 by $0.80, Fidelity Earnings reports. The business had revenue of $294.45 million during the quarter, compared to analyst estimates of $12.00 million. The business’s revenue for the quarter was up 4124.5% compared to the same quarter last year. During the same period in the previous year, the company posted ($0.26) EPS.
NASDAQ:LXRX traded down $0.36 during trading hours on Friday, hitting $3.52. 1,316,800 shares of the stock were exchanged, compared to its average volume of 1,292,482. The firm’s fifty day moving average price is $3.52 and its 200 day moving average price is $4.21. Lexicon Pharmaceuticals has a 52-week low of $1.13 and a 52-week high of $9.15. The company has a market cap of $419.77 million, a P/E ratio of -3.09 and a beta of 0.95.
In other news, CEO Lonnel Coats purchased 50,000 shares of the firm’s stock in a transaction on Tuesday, September 17th. The shares were bought at an average cost of $3.13 per share, for a total transaction of $156,500.00. Following the completion of the purchase, the chief executive officer now directly owns 127,639 shares of the company’s stock, valued at $399,510.07. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director Christopher J. Sobecki purchased 25,000 shares of the firm’s stock in a transaction on Monday, September 16th. The shares were purchased at an average price of $2.55 per share, for a total transaction of $63,750.00. Following the completion of the purchase, the director now directly owns 112,493 shares of the company’s stock, valued at $286,857.15. The disclosure for this purchase can be found here. Insiders have acquired 255,749 shares of company stock worth $578,510 over the last 90 days. 6.40% of the stock is owned by insiders.
A number of equities analysts recently weighed in on LXRX shares. ValuEngine raised Lexicon Pharmaceuticals from a “strong sell” rating to a “sell” rating in a report on Wednesday, October 2nd. Gabelli raised Lexicon Pharmaceuticals from a “hold” rating to a “buy” rating and set a $3.00 price target for the company in a report on Wednesday, September 11th. Citigroup cut Lexicon Pharmaceuticals from a “buy” rating to a “neutral” rating and upped their price target for the stock from $3.00 to $4.00 in a report on Friday. Stifel Nicolaus cut Lexicon Pharmaceuticals from a “buy” rating to a “hold” rating and reduced their price target for the stock from $10.00 to $4.00 in a report on Monday, July 29th. Finally, BidaskClub cut Lexicon Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a report on Tuesday, November 5th. One analyst has rated the stock with a sell rating, three have given a hold rating and five have issued a buy rating to the company. Lexicon Pharmaceuticals presently has an average rating of “Hold” and a consensus price target of $6.45.
About Lexicon Pharmaceuticals
Lexicon Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of pharmaceutical products. The company offers XERMELO, an orally-delivered small molecule drug candidate for the treatment of carcinoid syndrome diarrhea in combination with somatostatin analog therapy in adults.
See Also: Trading on Margin
Receive News & Ratings for Lexicon Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lexicon Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.